Neurocrine Biosciences Inc NBIX
News
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Neurocrine Biosciences to Participate at Investor Conferences in September
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Neurocrine Biosciences Gets FDA Breakthrough Therapy Status for Genetic Disorder Treatment
Lions Gate shares rise on surprise profit, Plug Power stock plunges on supply warning and more moving stocks
Neurocrine Biosciences shares drop as trial failures may 'stunt momentum,' analysts say